Moderna to Present Promising Phase 1/2 Clinical and Safety Data for Cancer Antigen Therapy mRNA-4359 at ESMO 2025
Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts.
Moderna Inc. (MRNA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 15,157 | $391,505 | 0.19% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.53 | 57,493 | $1,812,754.29 | 9,210,686 | 2025-03-03 | Filing | |
| $31.04 | 102,821 | $3,191,563.84 | 9,153,193 | 2025-03-03 | Filing | |
| $31.76 | 31,620 | $1,004,251.20 | 312,027 | 2025-03-03 | Filing | |
| $19.00 | 52,631 | $999,989.00 | 420,407 | 2020-02-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.00 | 312 | $8,736.00 | 580 | 2025-06-11 | Filing | |
| $44.68 | 529 | $23,637.31 | 20,446 | 2024-12-09 | Filing | |
| $43.30 | 112 | $4,849.28 | 19,837 | 2024-12-03 | Filing | |
| $43.30 | 314 | $13,595.29 | 1,443,904 | 2024-12-03 | Filing | |
| $42.79 | 1,420 | $60,760.52 | 11,066 | 2024-11-29 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,130,724 | $80,866,601 | 0.47% | |
| 2. | 1,128,434 | $29,147,450 | 0.41% | |
| 3. | 658,881 | $17,018,896 | 2.55% | |
| 4. | 324,665 | $8,386,097 | 0.17% | |
| 5. | 221,804 | $5,729,197 | 0.02% |
News See All
14 Best High Volume Stocks to Buy According to Wall Street Analysts
On October 9, Keith Buchanan, Senior Portfolio Manager at GLOBALT Investments, appeared on CNBC and stated that the markets show mixed signals of risk and optimism.
Brookline Reaffirms Price Target for Moderna (MRNA) After Strong mRNA-1283 Vaccine Results
Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
Moderna, Inc. (MRNA) Advances Flu, RSV, and Cancer mRNA Therapies Beyond COVID
Moderna, Inc. (NASDAQ:MRNA), a Cambridge-based biotechnology leader, specializes in mRNA therapeutics and vaccines, including its flagship COVID-19 vaccine.
Top 10 AI-Powered Biotech Stocks to Buy Now
The head biotech analyst at Goldman Sachs, Salveen Richter, made an appearance on CNBC's "Squawk Box" on July 25 to discuss a variety of topics, including the status of the biotech industry and what to...
I Thought Of Moderna, Inc. (MRNA) After Florida's Vaccine Rules, Says Jim Cramer
Moderna, Inc. (NASDAQ:MRNA) is the ill-fated vaccine company that has continued to struggle after the COVID-19 pandemic’s end.
10 Stocks Jim Cramer Discussed As He Warned About Big Risk To Big Tech
In his recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed how the threat of fines, levies, or tariffs against American companies by European nations was being overlooked.
Moderna (MRNA) Gains FDA Nod for Next-Gen COVID-19 Vaccine Targeting LP.8.1 Variant
Moderna, Inc. (NASDAQ:MRNA) ranks among the best mid-cap stocks with huge upside potential. Moderna, Inc.
12 Best Mid-Cap Stocks with Huge Upside Potential
The Commerce Department said on August 29 that core inflation, which does not include food and energy expenses, stood at a 2.9% seasonally adjusted annual rate based on the personal consumption expenditures...
Hedge Fund Resource Center Billionaire Hedge Funds
